Troutman Pepper Helps Cagent Vascular Inc. Secure Financing for First-of-its-Kind Blood Flow Restoration Tech

PHILADELPHIA – Troutman Pepper counseled Cagent Vascular Inc., a developer of next generation angioplasty balloons using proprietary serration technology, in connection with the recent investment of $9 million by Sectoral Asset Management. The proceeds will be used to accelerate the commercialization and scaling of manufacturing for the Serranator® below-the-knee (BTK) product. Further uses of proceeds include expanding the product offering to include larger sizes to treat the above-the-knee arteries.

The Serranator® PTA Serration Balloon Catheter is an angioplasty device with serrated metal strips embedded on a semi-compliant balloon. The Serranator’s unique technology is designed to create multiple longitudinal lines of interrupted micro-serrations within the luminal surface to aid in arterial expansion.

The Troutman Pepper team advising Cagent Vascular is led by Chris Miller and includes David Gallagher, Mike Crumbock, Saba Ashraf, Reid Oetting, and Dawn Hall.

Troutman Pepper regularly counsels pharmaceutical, biotech, medical device, diagnostics, and other life sciences clients on all types of corporate matters, including seed and later-stage venture capital financings. The multidisciplinary team applies deep industry know-how and market insight to provide holistic guidance throughout their business cycles.

About Troutman Pepper
Troutman Pepper is a national law firm with more than 1,200 attorneys strategically located in 23 U.S. cities. The firm’s litigation, transactional, and regulatory practices advise a diverse client base, from start-ups to multinational enterprises. The firm provides sophisticated legal solutions to clients’ most pressing business challenges, with depth across industry sectors, including health sciences, energy, real estate, insurance, finance, private equity, construction, and technology, among others. Learn more at troutman.com